All Outputs (5)

Ca2+ Influx through TRPC Channels Is Regulated by Homocysteine–Copper Complexes (2023)
Journal Article
Chen, G.-L., Zeng, B., Jiang, H., Daskoulidou, N., Saurabh, R., Chitando, R. J., & Xu, S.-Z. (2023). Ca2+ Influx through TRPC Channels Is Regulated by Homocysteine–Copper Complexes. Biomolecules, 13(6), Article 952. https://doi.org/10.3390/biom13060952

An elevated level of circulating homocysteine (Hcy) has been regarded as an independent risk factor for cardiovascular disease; however, the clinical benefit of Hcy lowering-therapy is not satisfying. To explore potential unrevealed mechanisms, we in... Read More about Ca2+ Influx through TRPC Channels Is Regulated by Homocysteine–Copper Complexes.

Recent advances in drug discovery for diabetic kidney disease (2020)
Journal Article
Danta, C. C., Boa, A. N., Bhandari, S., Sathyapalan, T., & Xu, S. Z. (2021). Recent advances in drug discovery for diabetic kidney disease. Expert Opinion on Drug Discovery, 16(4), 447-461. https://doi.org/10.1080/17460441.2021.1832077

Introduction: Diabetic kidney disease (DKD) is a leading cause of end-stage renal disease (ESRD), and 40% of patients with diabetes develop DKD. Although some pathophysiological mechanisms and drug targets of DKD have been described, the effectivenes... Read More about Recent advances in drug discovery for diabetic kidney disease.

Mibefradil, a T-type Ca2+ channel blocker also blocks Orai channels by action at the extracellular surface (2019)
Journal Article
Li, P., Rubaiy, H. N., Chen, G.-L., Hallett, T., Zaibi, N., Zeng, B., Saurabh, R., & Xu, S.-Z. (2019). Mibefradil, a T-type Ca2+ channel blocker also blocks Orai channels by action at the extracellular surface. British Journal of Pharmacology, 176, 3845–3856. https://doi.org/10.1111/bph.14788

Background and purpose
Mibefradil (Mib), a T‐type Ca2+ channel blocker, has been investigated for treating solid tumours. However, its underlying mechanisms are still unclear. Here we aimed to investigate the pharmacological aspect of Mib on ORAI st... Read More about Mibefradil, a T-type Ca2+ channel blocker also blocks Orai channels by action at the extracellular surface.

Pharmacological comparison of novel synthetic fenamate analogues with econazole and 2-APB on the inhibition of TRPM2 channels (2012)
Journal Article
Chen, G.-L., Zeng, B., Eastmond, S., Elsenussi, S. E., Boa, A. N., & Xu, S.-Z. (2012). Pharmacological comparison of novel synthetic fenamate analogues with econazole and 2-APB on the inhibition of TRPM2 channels. British Journal of Pharmacology, 167(6), 1232-1243. https://doi.org/10.1111/j.1476-5381.2012.02058.x

BACKGROUND: Fenamate analogues, econazole and 2-APB are inhibitors of TRPM2 channels, which have been used as research tools. However, these compounds have different chemical structures and therapeutic applications. Here we aimed to investigate the p... Read More about Pharmacological comparison of novel synthetic fenamate analogues with econazole and 2-APB on the inhibition of TRPM2 channels.

Effect of non-steroidal anti-inflammatory drugs and new fenamate analogues on TRPC4 and TRPC5 channels (2012)
Journal Article
Jiang, H., Zeng, B., Chen, G.-L., Bot, D., Eastmond, S., Elsenussi, S. E., Atkin, S. L., Boa, A. N., & Xu, S.-Z. (2012). Effect of non-steroidal anti-inflammatory drugs and new fenamate analogues on TRPC4 and TRPC5 channels. Biochemical Pharmacology, 83(7), 923-931. https://doi.org/10.1016/j.bcp.2012.01.014

Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used anti-inflammatory therapeutic agents,among which the fenamate analogues play important roles in regulating intracellular Ca²⁺ transient and ion channels. However, the effect of... Read More about Effect of non-steroidal anti-inflammatory drugs and new fenamate analogues on TRPC4 and TRPC5 channels.